Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -48.81 Million USD | -52.89% |
| 2022 | -31.93 Million USD | -29.88% |
| 2021 | -24.58 Million USD | -11.56% |
| 2020 | -22.03 Million USD | -1.43% |
| 2019 | -21.72 Million USD | 8.15% |
| 2018 | -23.65 Million USD | 11.08% |
| 2017 | -26.6 Million USD | -9.37% |
| 2016 | -24.32 Million USD | -15.68% |
| 2015 | -21.02 Million USD | 14.83% |
| 2014 | -24.68 Million USD | -129.14% |
| 2013 | -10.77 Million USD | -28.85% |
| 2012 | -8.36 Million USD | -81363.53% |
| 2011 | 10.28 Thousand USD | 514.64% |
| 2010 | 1674.00 USD | 107.5% |
| 2009 | -22.33 Thousand USD | 28.52% |
| 2008 | -31.24 Thousand USD | -111.1% |
| 2007 | -14.8 Thousand USD | 19.58% |
| 2006 | -18.4 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -11.35 Million USD | -30.95% |
| 2024 Q1 | -8.67 Million USD | 7.01% |
| 2023 FY | -48.81 Million USD | -52.89% |
| 2023 Q3 | -13.27 Million USD | 12.55% |
| 2023 Q2 | -15.18 Million USD | -44.72% |
| 2023 Q1 | -10.49 Million USD | -4.87% |
| 2023 Q4 | -9.32 Million USD | 29.77% |
| 2022 Q3 | -9.14 Million USD | -17.79% |
| 2022 FY | -31.93 Million USD | -29.88% |
| 2022 Q1 | -5.09 Million USD | 36.4% |
| 2022 Q2 | -7.76 Million USD | -52.47% |
| 2022 Q4 | -10 Million USD | -9.33% |
| 2021 Q2 | -5.02 Million USD | 5.62% |
| 2021 Q4 | -8.01 Million USD | -24.71% |
| 2021 FY | -24.58 Million USD | -11.56% |
| 2021 Q1 | -5.32 Million USD | 16.61% |
| 2021 Q3 | -6.42 Million USD | -27.92% |
| 2020 Q3 | -5.54 Million USD | -19.78% |
| 2020 FY | -22.03 Million USD | -1.43% |
| 2020 Q2 | -4.62 Million USD | 18.43% |
| 2020 Q1 | -5.67 Million USD | -23.2% |
| 2020 Q4 | -6.38 Million USD | -15.16% |
| 2019 Q1 | -5.67 Million USD | 10.28% |
| 2019 FY | -21.72 Million USD | 8.15% |
| 2019 Q2 | -5.02 Million USD | 11.35% |
| 2019 Q3 | -6.59 Million USD | -31.28% |
| 2019 Q4 | -4.6 Million USD | 30.26% |
| 2018 Q3 | -6.14 Million USD | -26.43% |
| 2018 FY | -23.65 Million USD | 11.08% |
| 2018 Q1 | -6.31 Million USD | -22.3% |
| 2018 Q2 | -4.86 Million USD | 22.99% |
| 2018 Q4 | -6.31 Million USD | -2.79% |
| 2017 FY | -26.6 Million USD | -9.37% |
| 2017 Q4 | -5.16 Million USD | 18.34% |
| 2017 Q3 | -6.32 Million USD | 10.36% |
| 2017 Q2 | -7.05 Million USD | 12.5% |
| 2017 Q1 | -8.06 Million USD | -20.4% |
| 2016 Q4 | -6.69 Million USD | -1.47% |
| 2016 Q2 | -6.62 Million USD | -50.43% |
| 2016 Q3 | -6.59 Million USD | 0.38% |
| 2016 Q1 | -4.4 Million USD | 32.68% |
| 2016 FY | -24.32 Million USD | -15.68% |
| 2015 FY | -21.02 Million USD | 14.83% |
| 2015 Q4 | -6.54 Million USD | -65.74% |
| 2015 Q3 | -3.94 Million USD | 47.13% |
| 2015 Q2 | -7.46 Million USD | -142.73% |
| 2015 Q1 | -3.07 Million USD | 43.33% |
| 2014 Q4 | -5.42 Million USD | 10.71% |
| 2014 FY | -24.68 Million USD | -129.14% |
| 2014 Q1 | -16.69 Million USD | -184.01% |
| 2014 Q2 | 3.51 Million USD | 121.05% |
| 2014 Q3 | -6.07 Million USD | -272.88% |
| 2013 Q1 | -689.02 Thousand USD | 91.74% |
| 2013 Q2 | -2.78 Million USD | -304.05% |
| 2013 Q3 | -1.42 Million USD | 48.96% |
| 2013 Q4 | -5.87 Million USD | -313.81% |
| 2013 FY | -10.77 Million USD | -28.85% |
| 2012 FY | -8.36 Million USD | -81363.53% |
| 2012 Q1 | -9628.00 USD | -263.73% |
| 2012 Q3 | -3.01 Million USD | -92.79% |
| 2012 Q4 | -8.34 Million USD | -176.9% |
| 2012 Q2 | -1.56 Million USD | -16129.65% |
| 2011 FY | 10.28 Thousand USD | 514.64% |
| 2011 Q1 | -4005.00 USD | 53.0% |
| 2011 Q2 | 20.45 Thousand USD | 610.74% |
| 2011 Q3 | -3514.00 USD | -117.18% |
| 2011 Q4 | -2647.00 USD | 24.67% |
| 2010 Q1 | -8296.00 USD | 12.65% |
| 2010 Q4 | -8522.00 USD | 11.95% |
| 2010 Q3 | -9679.00 USD | -134.36% |
| 2010 FY | 1674.00 USD | 107.5% |
| 2010 Q2 | 28.17 Thousand USD | 439.57% |
| 2009 Q3 | -3849.00 USD | -4.82% |
| 2009 Q1 | -5313.00 USD | 30.2% |
| 2009 FY | -22.33 Thousand USD | 28.52% |
| 2009 Q4 | -9497.00 USD | -146.74% |
| 2009 Q2 | -3672.00 USD | 30.89% |
| 2008 Q1 | -10.82 Thousand USD | -133.51% |
| 2008 Q2 | -9473.00 USD | 12.51% |
| 2008 Q3 | -3330.00 USD | 64.85% |
| 2008 Q4 | -7612.00 USD | -128.59% |
| 2008 FY | -31.24 Thousand USD | -111.1% |
| 2007 Q3 | -6353.00 USD | -88.24% |
| 2007 Q2 | -3375.00 USD | -675.86% |
| 2007 FY | -14.8 Thousand USD | 19.58% |
| 2007 Q1 | -435.00 USD | 94.81% |
| 2007 Q4 | -4637.00 USD | 27.01% |
| 2006 Q3 | -9812.00 USD | 0.0% |
| 2006 Q4 | -8374.00 USD | 14.66% |
| 2006 FY | -18.4 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | -68.559% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -465.547% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 29.295% |
| Azitra, Inc. | -11.28 Million USD | -332.639% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -539.481% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -561.419% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | -67.093% |
| CEL-SCI Corporation | -32.36 Million USD | -50.832% |
| iBio, Inc. | -24.9 Million USD | -96.001% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | -127.208% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -146.893% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | -112.789% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -221.655% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -406.411% |
| NanoViricides, Inc. | -8.29 Million USD | -488.584% |
| Oragenics, Inc. | -20.65 Million USD | -136.341% |
| BiomX Inc. | -26.16 Million USD | -86.549% |
| BiomX Inc. | -26.16 Million USD | -86.549% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 687.32% |
| Palatin Technologies, Inc. | -29.73 Million USD | -64.171% |
| Scorpius Holdings, Inc. | -45.21 Million USD | -7.963% |